By Suherman Candra Maholtra 
In a significant advancement for the fields of synthetic biology and infectious disease prevention, researchers at the University of Cincinnati (UC) have successfully engineered a strain of probiotic bacteria capable of delivering both vaccines and antiviral therapies through simple oral administration. This pioneering research, led by Nalinikanth Kotagiri, PhD, an associate professor at the UC James L. Winkle College of Pharmacy, utilizes the human body’s own microbiome to create a self-sustaining bio-factory for medicine. Published recently in the journal Gut Microbes, the study demonstrates a "plug-and-play" platform that could revolutionize how global health authorities respond to viral outbreaks by bypassing the need for needles and complex cold-chain logistics.
The Evolution of Probiotic Engineering at the University of Cincinnati
The project originated in Dr. Kotagiri’s laboratory, which has long been dedicated to the modification of beneficial bacteria for clinical use. Prior to this breakthrough, the team focused on engineering probiotics to dismantle the defensive microenvironments of cancerous tumors and to assist in the imaging and diagnosis of persistent lung infections. The transition to viral defense represented a logical evolution of their "chassis" model—using a well-understood biological foundation to carry diverse medical payloads.
The team utilized Escherichia coli Nissle 1917 (EcN), a strain of bacteria that has been used safely as a commercial probiotic for over a century. Unlike pathogenic E. coli, the Nissle strain does not produce toxins and is known to support intestinal health. By selecting this specific bacterium, the researchers ensured that the delivery vehicle was already recognized as safe by regulatory standards, potentially shortening the path toward future human clinical trials.
The core question driving the research was whether this bacterial chassis could be programmed to ferry antiviral therapeutic agents or vaccine antigens directly to the gastrointestinal tract—a major portal of entry for many viruses. For their proof-of-concept, the team focused on the SARS-CoV-2 virus, the pathogen responsible for the COVID-19 pandemic.
Addressing the Limitations of Current Vaccination Methods
While the rapid development of mRNA and viral vector vaccines was instrumental in curbing the COVID-19 pandemic, these technologies face two significant hurdles: logistical complexity and the nature of the immune response they generate. Traditional vaccines are typically administered via intramuscular injection, which generates systemic immunity. This means antibodies (primarily Immunoglobulin G or IgG) circulate in the bloodstream to prevent severe disease.
However, many viruses, including coronaviruses, influenza, and noroviruses, enter the body through mucosal surfaces such as the lining of the gut and the respiratory tract. Systemic vaccines are often less effective at generating "mucosal immunity," which relies on Secretory Immunoglobulin A (IgA) to block the virus at the very point of entry.
Furthermore, current vaccines require a "cold chain"—a temperature-controlled supply chain—to remain viable. This requirement creates immense barriers in developing nations or rural areas where refrigeration is inconsistent. Dr. Kotagiri noted that oral delivery addresses both issues: it targets the mucosal surfaces where pathogens first gain a foothold while simultaneously eliminating the need for needles and expensive cold-storage infrastructure.
The Mechanism: Outer-Membrane Vesicles as Biological Postmasters
The UC team’s breakthrough lies in how they solved the problem of antigen presentation. Most engineered bacteria keep their therapeutic cargo trapped inside the cell wall. For a vaccine to be effective, the immune system must be able to "see" and recognize the viral proteins.
To overcome this, the researchers engineered the bacteria to display viral proteins on their surface. They also leveraged a natural biological process: the shedding of outer-membrane vesicles (OMVs). These are nano-sized spheres that bacteria naturally release into their environment. The team designed the probiotics so that these OMVs would carry a concentrated payload of viral antigens or therapeutic proteins.
Once the probiotic is ingested, it colonizes the gut. The bacteria then begin producing and shedding these OMVs. Because of their microscopic size, the OMVs can traverse the gut epithelium (the lining of the intestines), enter the bloodstream, and distribute their therapeutic cargo to distant tissues, including the lungs.
Nitin S. Kamble, PhD, a research scientist in Kotagiri’s lab and the study’s first author, described the OMVs as "natural postmasters." By systematically screening anchor motifs and expression cassettes, Kamble optimized the density of the antigens on the bacterial surface, ensuring a robust immune response. For the vaccine version of the platform, the bacteria were programmed to express the SARS-CoV-2 spike protein—the same protein targeted by current mRNA vaccines.
Comparative Data: Oral Delivery vs. Intramuscular Injection
The efficacy of this oral platform was tested in preclinical animal models, yielding results that have significant implications for the future of vaccinology. In a two-dose oral regimen, the engineered bacteria generated blood-borne systemic antibody levels that were comparable to those produced by traditional intramuscular mRNA vaccinations.
More importantly, the oral probiotic produced markedly higher levels of Secretory IgA in both the gut and the airways. This confirms that the oral route is superior for establishing mucosal immunity. By creating a "first line of defense" in the respiratory and gastrointestinal tracts, this method could potentially prevent infection entirely, rather than just reducing the severity of the illness.
In addition to the vaccine component, the team developed a "therapy platform" intended for use after a person has already been infected. This version of the E. coli Nissle 1917 was designed to display anti-spike nanobodies. Nanobodies are specialized antibodies that are roughly one-tenth the size of conventional monoclonal antibodies. Their small size allows them to penetrate tissues more effectively and bind to viral structures that larger antibodies might miss.
The study found that these nanobodies, released via OMVs from the gut-dwelling probiotics, successfully reached the bloodstream and accumulated in lung tissue. In ex-vivo assays, these nanobodies were shown to effectively neutralize the SARS-CoV-2 virus.
A Self-Renewing Depot for Antiviral Treatment
One of the most striking advantages of the probiotic delivery system is its longevity. Current antiviral treatments, such as intravenous (IV) infusions of monoclonal antibodies, deliver a large "one-time" dose that eventually leaves the system. In contrast, because the engineered probiotic can reside in the human gut for days or even weeks, it acts as a self-renewing and sustained depot of medicine.
This continuous production of nanobodies or antigens could provide long-lasting protection or treatment without the need for repeated clinic visits. "A unique aspect of this approach is the use of OMVs to deliver a concentrated payload of therapeutic proteins, making them ideal for mucosal delivery," Kamble explained.
Broader Implications and Future Adaptations
The University of Cincinnati team views this technology as a universal platform rather than a COVID-specific tool. Because the bacterial chassis has already been optimized, it can be quickly adapted to combat other viral threats. By simply "plugging in" different nanobodies or antigens, the platform could be used to develop oral vaccines and treatments for the seasonal flu, norovirus (often called the "stomach flu"), and other emerging viral pathogens.
"All that optimization was necessary for us to prove that this is a platform that we can take forward," Kotagiri said. He envisions a future where a single probiotic dose could contain both the vaccine and the therapy components, providing a dual layer of protection.
The economic and social implications of such a platform are profound. An oral, shelf-stable vaccine could be distributed through standard mail or over-the-counter at pharmacies, significantly increasing global vaccination rates and reducing the burden on healthcare systems. It also offers a more palatable option for individuals with needle phobias, potentially increasing compliance in pediatric and adult populations alike.
Safety and Next Steps
Safety remains a primary focus for the researchers. While E. coli Nissle 1917 has a long history of safe use, the team conducted rigorous testing to ensure the engineered modifications did not introduce adverse effects. To date, animal models have shown no adverse immune responses or side effects from the engineered bacteria.
The researchers have already filed a patent application with the U.S. Patent and Trademark Office through the University of Cincinnati. The next phase of research will involve full viral-challenge studies to further validate the protective capabilities of the platform before moving toward human clinical trials.
The study was supported by several prestigious grants, including funding from the National Institutes of Health (NIH) and the Congressionally Directed Medical Research Programs (CDMRP), as well as support from the University of Cincinnati Office of Research.
As the world continues to navigate the challenges of infectious disease management, the work of Dr. Kotagiri and his team represents a shift toward more accessible, durable, and physiologically targeted medicine. By turning a common probiotic into a sophisticated delivery vehicle, the University of Cincinnati has opened a new frontier in the fight against global viral threats.